NasdaqGS:VRTXBiotechs
Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?
Earlier in July 2026, U.S. regulators expanded approval of Vertex’s gene-editing therapy Casgevy to children as young as 2 with sickle cell disease or transfusion-dependent thalassemia, while Canada’s pan-Canadian Pharmaceutical Alliance signed a Letter of Intent with Vertex to enable public reimbursement discussions for its cystic fibrosis therapy ALYFTREK.
These moves deepen Vertex’s reach in severe genetic diseases by both widening the eligible patient pool for Casgevy and advancing payer...